Corbus Pharmaceuticals Announces First Patient Dosed in TEMPO-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal Cancer
Corbus Pharmaceuticals reports dosing the first patient in TEMPO-1, a randomized registrational study of CRB-701 in second-line and beyond oropharyngeal squamous cell carcinoma (OPSCC). The trial (n=250) uses objective response rate (ORR) as its primary endpoint to support potential accelerated approval, and Corbus cites Phase 1/2 data showing a confirmed ORR of 42.9% at the 3.6 mg/kg dose.